Journal Article Epublish 1 citation
PubMed: 38535125 DOI: 10.3390/ijns10010021
Iowa Newborn Screening Program Experience with Hemoglobinopathy Screening over the Last Two Decades and Its Increasing Global Relevance.
Int J Neonatal Screen 10(1)
Authors: Ryan Jilek, Jennifer Marcy, Carol Johnson, Georgianne Younger, Amy Calhoun, Moon Ley Tung
Affiliations
- Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
- Stead Family Department of Pediatrics, Division of Medical Genetics and Genomics, Iowa City, IA 52242, USA. Iowa Newborn Screening Program, Iowa City, IA 52242, USA.
- Stead Family Department of Pediatrics, Division of Medical Genetics and Genomics, Iowa City, IA 52242, USA.
- Iowa Newborn Screening Program, Iowa City, IA 52242, USA.
Abstract
Hemoglobinopathies are the commonest monogenic disorder worldwide, with approximately seven percent of the world population being carriers of hemoglobinopathies. The healthcare utilization impact of thalassemia has resulted in global public health initiatives to screen for hemoglobinopathies, especially sickle cell disease (SCD). The Iowa Newborn Screening Program (INSP) has been in place for more than 50 years with a primary focus on detecting SCD. Recent changes in migration patterns have led to a global distribution of hemoglobinopathies in the western world, which has translated to an increase in the diagnosis of SCD and the incidental detection of non-sickling hemoglobinopathies within the INSP. This study documents the birth prevalence of hemoglobinopathies diagnosed in newborns through the INSP and highlights the need for newborn screening programs to evolve to meet the healthcare needs of underserved, minority populations.
MeSH
Thalassemia, Hemoglobinopathies, Neonatal Screening, Infant, Newborn